Patents by Inventor Kyle Jacoby

Kyle Jacoby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HOMOLOGY DIRECTED REPAIR COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20260049339
    Abstract: The present disclosure provides improved compositions for the homology directed repair of the human globin locus for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy.
    Type: Application
    Filed: July 16, 2025
    Publication date: February 19, 2026
    Applicants: Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute, Fred Hutchinson Cancer Center
    Inventors: Andrew Scharenberg, Kyle Jacoby, Hans-Peter Kiem, David J. Rawlings, Christopher Lux, Sowmya Pattabhi, Olivier Humbert
  • SPATIAL CHARACTERIZATION OF THE FECAL MICROBIOME
    Publication number: 20260036581
    Abstract: Disclosed herein is a method of evaluating the fecal microbiome of a subject comprising determining a spatial characterization of the fecal microbiome.
    Type: Application
    Filed: August 1, 2025
    Publication date: February 5, 2026
    Applicant: Kanvas Biosciences, Inc.
    Inventors: Prateek Sehgal, Gregory Booth, Philip Burnham, Matthew Cheng, Kevin Cutler, Iwijn De Vlaminck, Anjali Doshi, Kyle Jacoby, Gaetano Scuderi, Hao Shi, Lee Swem, Maya Trisolini
  • MICROBIAL CONSORTIA
    Publication number: 20260007704
    Abstract: The present disclosure provides microbial consortia, and methods of making and using the same, comprising a complete microbiome replacement capable of stable engraftment in the gastrointestinal tract for the treatment of IBD, ulcerative colitis, and Crohn's disease.
    Type: Application
    Filed: September 10, 2025
    Publication date: January 8, 2026
    Applicant: KANVAS BIOSCIENCES, INC.
    Inventors: Robert Lee SWEM, Joshua J. HAMILTON, James BERLEMAN, Kyle JACOBY, Ariana M. CIGLAR, Anupreet PARMAR, Aditya BHALLA, Pawan KUMAR
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
    Publication number: 20260001931
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.
    Type: Application
    Filed: February 4, 2025
    Publication date: January 1, 2026
    Applicant: ADOC SSF, LLC
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
  • Homology directed repair compositions for the treatment of hemoglobinopathies
    Patent number: 12385070
    Abstract: The present disclosure provides improved compositions for the homology directed repair of the human globin locus for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy.
    Type: Grant
    Filed: June 29, 2023
    Date of Patent: August 12, 2025
    Assignees: Seattle Children's Hospital, Fred Hutchinson Cancer Center
    Inventors: Andrew Scharenberg, Kyle Jacoby, Hans-Peter Kiem, David J. Rawlings, Christopher Lux, Sowmya Pattabhi, Olivier M. Humbert
  • PRIMARY CELL GENE EDITING
    Publication number: 20250250587
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Application
    Filed: April 25, 2025
    Publication date: August 7, 2025
    Applicant: ADOC SSF, LLC
    Inventors: Kyle Jacoby, Alex Franzusoff
  • Methods of performing GUIDE-Seq on primary human T cells
    Patent number: 12359247
    Abstract: Disclosed herein are methods for identifying the effects, including off target effect, of genomic modification of primary cells. These methods are performed with high accuracy suitable for validating therapeutic T-cell engineering approaches.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: July 15, 2025
    Assignee: ADOC SSF, LLC
    Inventors: Xiaoyan Robert Bao, Kyle Jacoby, William Lu
  • Compositions and methods for the treatment of cancer using a CD8 engineered T cell therapy
    Patent number: 12247061
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: March 11, 2025
    Assignee: ADOC SSF, LLC
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
  • Homology directed repair compositions for the treatment of hemoglobinopathies
    Patent number: 12110499
    Abstract: The present disclosure provides improved compositions for the homology directed repair of the human globin locus for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: October 8, 2024
    Assignee: Seattle Children's Hospital
    Inventors: Andrew Scharenberg, Kyle Jacoby, Hans-Peter Kiem, David J. Rawlings, Christopher Lux, Sowmya Pattabhi, Olivier M. Humbert
  • HOMOLOGY DIRECTED REPAIR COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20240124896
    Abstract: The present disclosure provides improved compositions for the homology directed repair of the human globin locus for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy.
    Type: Application
    Filed: June 29, 2023
    Publication date: April 18, 2024
    Applicants: Seattle Children's Hospital (d/b/a Seattle Children's Research Institute), Fred Hutchinson Cancer Center
    Inventors: Andrew Scharenberg, Kyle Jacoby, Hans-Peter Kiem, David J. Rawlings, Christopher Lux, Sowmya Pattabhi, Olivier M. Humbert
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFßRII ENGINEERED T CELL THERAPY
    Publication number: 20240066063
    Abstract: Compositions comprising and methods for the treatment of cancer using a NeoTCR based cell therapy with a modified TGF?RII expression.
    Type: Application
    Filed: May 18, 2023
    Publication date: February 29, 2024
    Applicant: PACT PHARMA, INC.
    Inventors: Charles W. TRAN, John D. Gagnon, Barbara Sennino, Stefanie Mandl-Cashman, Kyle Jacoby, William Lu, Michael Mayne Dubreuil, James S. Byers, III, Michal Mass, Alex Franzusoff
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING NEXT GENERATION ENGINEERED T CELL THERAPY
    Publication number: 20230355762
    Abstract: Compositions comprising and methods for the treatment of cancer using a NeoTCR based cell therapy with a secondary Payload in an expression construct.
    Type: Application
    Filed: April 25, 2023
    Publication date: November 9, 2023
    Applicant: PACT PHARMA, INC.
    Inventors: Michal Mass, William Lu, Kyle Jacoby, Michael Mayne Dubreuil, Barbara Sennino, Stefanie Mandl-Cashman, James S. Byers, III
  • MICROBIAL CONSORTIA
    Publication number: 20230165913
    Abstract: The present disclosure provides microbial consortia comprising O. formigenes capable of stable engraftment in the gastrointestinal tract of a subject and methods of using and making the same.
    Type: Application
    Filed: December 1, 2022
    Publication date: June 1, 2023
    Applicant: Federation Bio, Inc.
    Inventors: Lee Robert Swem, Pawan Kumar, Aditya Bhalla, Shital A. Tripathi, Anupreet Parmar, Joshua J. Hamilton, Ariel R. Brumbaugh, Dante P. Ricci, Hans Richard William Layman, Ariana M. Ciglar, James Berleman, Zachary Walters, Kyle Jacoby, Nicholas D. Youngblut, Andreas Grauer, Emily Drabant Conley, Heather Romasko
  • METHODS OF DETERMINING GENE EDITING EFICIENCIES IN CELLS
    Publication number: 20230136076
    Abstract: Methods of detecting the efficacy and presence of a biologic drug which uses one or more 2A peptide in its manufacture and/or final pharmaceutical formulation.
    Type: Application
    Filed: October 24, 2022
    Publication date: May 4, 2023
    Applicant: Pact Pharma, Inc.
    Inventors: Kyle JACOBY, Barbara Sennino, Susan Foy, Theresa L. Hunter
  • LONG POLY(A) PLASMIDS AND METHODS FOR INTRODUCTION OF LONG POLY(A) SEQUENCES INTO THE PLASMID
    Publication number: 20230054471
    Abstract: Disclosed herein are polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, methods of engineering the polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, and methods of enhancing transcription, translation, and increasing stability of a polynucleotide.
    Type: Application
    Filed: July 11, 2022
    Publication date: February 23, 2023
    Inventors: Andrew M. Scharenberg, Kyle Jacoby, Alexandra E. Grier
  • Long poly(A) plasmids and methods for introduction of long poly(A) sequences into the plasmid
    Patent number: 11400169
    Abstract: Disclosed herein are polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, methods of engineering the polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, and methods of enhancing transcription, translation, and increasing stability of a polynucleotide.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: August 2, 2022
    Assignee: SEATTLE CHILDREN'S HOSPITAL
    Inventors: Andrew M. Scharenberg, Kyle Jacoby, Alexandra E. Grier
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
    Publication number: 20220193139
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.
    Type: Application
    Filed: March 10, 2022
    Publication date: June 23, 2022
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
  • Compositions and methods for the treatment of cancer using a CD8 engineered T cell therapy
    Patent number: 11304978
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: April 19, 2022
    Assignee: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
  • PERSONALIZED NEOANTIGEN-SPECIFIC ADOPTIVE CELL THERAPIES
    Publication number: 20220010274
    Abstract: Methods of genetically engineering NeoTCR Products comprising young T cells and methods of manufacturing such cell products.
    Type: Application
    Filed: September 28, 2021
    Publication date: January 13, 2022
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Susan Foy, Ines Mende, Stefanie Mandl-Cashman
  • PRIMARY CELL GENE EDITING
    Publication number: 20210395783
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Application
    Filed: August 12, 2021
    Publication date: December 23, 2021
    Applicant: PACT PHARMA, INC.
    Inventors: Kyle Jacoby, Alex Franzusoff